汇宇制药：注射用硫酸多黏菌素B获药品注册证书

Core Viewpoint - The company has received approval for the injectable colistin sulfate from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd., has been granted a drug registration certificate for injectable colistin sulfate [1] - Injectable colistin sulfate is classified as a Class 3 chemical drug with a specification of 500,000 units and a shelf life of 24 months [1] Group 2: Market Potential - The drug is intended for treating severe infections in adult patients caused by carbapenem-resistant Gram-negative bacteria, including meningitis and bacteremia caused by sensitive strains of Pseudomonas aeruginosa [1] - The projected sales revenue for injectable colistin sulfate in urban public hospitals in China for 2024 is estimated to be 529 million yuan [1] Group 3: Future Outlook - The company has initiated preparatory work for the product's market launch, but there is uncertainty regarding its potential to generate significant revenue in the future [1]